EMA Grants Orphan Drug Designation to Quoin’s QRX003
The European Medicines Agency granted orphan drug designation to QRX003 for treatment of peeling skin syndrome.
The European Medicines Agency granted orphan drug designation to QRX003 for treatment of peeling skin syndrome.